Javier San Martin
Chief Tech/Sci/R&D Officer at ATHIRA PHARMA, INC.
Net worth: 6 M $ as of 30/03/2024
Profile
Presently, Javier San Martin is Chief Medical Officer at Arrowhead Pharmaceuticals, Inc. He previously held the position of Executive Director-Bone Therapeutic Area at Amgen, Inc., Principal at Eli Lilly & Co., Senior VP-Global Clinical Development at Ultragenyx Pharmaceutical, Inc. and Senior Vice President-Clinical Development at Alder Biopharmaceuticals, Inc. He received a doctorate from Universidad de Buenos Aires.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 09/01/2024 | 198,497 ( 0.16% ) | 6 M $ | 30/03/2024 |
Javier San Martin active positions
| Companies | Position | Start |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Tech/Sci/R&D Officer | 14/04/2024 |
Former positions of Javier San Martin
| Companies | Position | End |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/01/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 31/10/2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Javier San Martin
| University of Buenos Aires School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
- Stock Market
- Insiders
- Javier San Martin
